IL-6 signaling drives fibroblast activation in tendinopathy, emerging as a promising therapeutic target for these increasingly prevalent and costly tendon conditions.
FMT alleviated the intestinal barrier damage caused by enterotoxigenic Escherichia coli infection in antibiotic-induced microbiome-disordered model through increasing the relative abundance of A. muciniphila in the intestine.
